|
1
|
Glass AG, Lacey JV, Carreon JD and Hoover
RN: Breast cancer incidence, 1980–2006: combined roles of
menopausal hormone therapy, screening mammography, and estrogen
receptor status. J Natl Cancer Inst. 99:1152–1161. 2007.
|
|
2
|
Tirapu I, Huarte E, Guiducci C, et al: Low
surface expression of B7-1 (CD80) is an immunoescape mechanism of
colon carcinoma. Cancer Res. 66:2442–2450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ugurel S, Uhlig D, Pföhler C, Tilgen W,
Schadendorf D and Reinhold U: Down-regulation of HLA class II and
costimulatory CD86/B7-2 on circulating monocytes from melanoma
patients. Cancer Immunol Immunother. 53:551–559. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carreno BM and Collins M: The B7 family of
ligands and its receptors: new pathways for costimulation and
inhibition of immune responses. Annu Rev Immunol. 20:29–53. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khoury SJ and Sayegh MH: The roles of the
new negative T cell costimulatory pathways in regulating
autoimmunity. Immunity. 20:529–538. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prasad DV, Nguyen T, Li Z, Yang Y, Duong
J, Wang Y and Dong C: Murine B7-H3 is a negative regulator of T
cells. J Immunol. 173:2500–2506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suh WK, Gajewska BU, Okada H, et al: The
B7 family member B7-H3 preferentially down-regulates T helper type
1-mediated immune responses. Nat Immunol. 4:899–906. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ling V, Wu PW, Spaulding V, Kieleczawa J,
Luxenberg D, Carreno BM and Collins M: Duplication of primate and
rodent B7-H3 immunoglobulin V- and C-like domains: divergent
history of functional redundancy and exon loss. Genomics.
82:365–377. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chapoval AI, Ni J, Lau JS, Wilcox RA,
Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K and Chen L:
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma
production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greenwald RJ, Freeman GJ and Sharpe AH:
The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang GB, Chen YJ, Shi Q, Ma HB, Ge Y,
Wang Q, Jiang Z, Xu Y and Zhang XG: Human recombinant B7-H3
expressed in E. coli enhances T lymphocyte proliferation and
IL-10 secretion in vitro. Acta Biochim Biophys Sin (Shanghai).
36:430–436. 2004.PubMed/NCBI
|
|
12
|
Moore KW, de Waal Malefyt R, Coffman RL
and O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu
Rev Immunol. 19:683–765. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Akdis CA and Blaser K: Mechanisms of
interleukin-10-mediated immune suppression. Immunology.
103:131–136. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Woo SU, Bae JW, Yang JH, Kim JH, Nam SJ
and Shin YK: Overexpression of interleukin-10 in sentinel lymph
node with breast cancer. Ann Surg Oncol. 14:3268–3273. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Llanes-Fernández L, Alvarez-Goyanes RI,
Arango-Prado Mdel C, et al: Relationship between IL-10 and tumor
markers in breast cancer patients. Breast. 15:482–489.
2006.PubMed/NCBI
|
|
16
|
Smith IE: New drugs for breast cancer.
Lancet. 360:790–792. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R,
Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell
lung cancer. Lung Cancer. 53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Crispen PL, Sheinin Y, Roth TJ, et al:
Tumor cell and tumor vasculature expression of B7-H3 predict
survival in clear cell renal cell carcinoma. Clin Cancer Res.
14:5150–5157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M,
Tan Y, Wang HT, Lu BF and Zhang XG: Clinical significance and
regulation of the costimulatory molecule B7-H3 in human colorectal
carcinoma. Cancer Immunol Immunother. 59:1163–1171. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loos M, Hedderich DM, Ottenhausen M, Giese
NA, Laschinger M, Esposito I, Kleeff J and Friess H: Expression of
the costimulatory molecule B7-H3 is associated with prolonged
survival in human pancreatic cancer. BMC Cancer. 9:4632009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu
KF, Zhao JM, Zhang GB and Zhang XG: Relationship between
co-stimulatory molecule B7-H3 expression and gastric carcinoma
histology and prognosis. World J Gastroenterol. 12:457–459.
2006.PubMed/NCBI
|
|
22
|
Ohigashi Y, Sho M, Yamada Y, et al:
Clinical significance of programmed death-1 ligand-1 and programmed
death-1 ligand-2 expression in human esophageal cancer. Clin Cancer
Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun Y, Liu J, Gao P, Wang Y and Liu C:
Expression of Ig-like transcript 4 inhibitory receptor in human
non-small cell lung cancer. Chest. 134:783–788. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kryczek I, Wei S, Zhu G, Myers L, Mottram
P, Cheng P, Chen L, Coukos G and Zou W: Relationship between B7-H4,
regulatory T cells, and patient outcome in human ovarian carcinoma.
Cancer Res. 67:8900–8905. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kryczek I, Zou L, Rodriguez P, et al:
B7-H4 expression identifies a novel suppressive macrophage
population in human ovarian carcinoma. J Exp Med. 203:871–881.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
García-Hernández ML, Hernández-Pando R,
Gariglio P and Berumen J: Interleukin-10 promotes B16-melanoma
growth by inhibition of macrophage functions and induction of
tumour and vascular cell proliferation. Immunology. 105:231–243.
2002.PubMed/NCBI
|
